Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

November
03
2016

Sensus Healthcare Reports Third Quarter 2016 Results

– Q3 revenues increased 58% year-over-year to $3.33 million – Worldwide installed base increased to 256 units BOCA RATON, Fla., Nov. 3, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in…

October
31
2016

Patients Benefit from Non-Surgical SRT

If you’ve been diagnosed with non-melanoma skin cancer, such as basal cell carcinoma or squamous cell carcinoma, you now have a new, non-surgical option for treatment. Superficial Radio Therapy (SRT) with the SRT-100™ delivers a…

October
26
2016

Physicians Prefer SRT Therapy for Treatment of Non-Melanoma Skin Cancer and Keloid Scars

Eighteen million people are affected by unsightly and sometimes painful keloid scars, and many of them go through life believing treatment for this embarrassing condition is next to impossible, if possible at all. You can…

October
20
2016

Sensus Healthcare to Announce Third Quarter 2016 Results on November 3, 2016

BOCA RATON, Fla., Oct. 20, 2016 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy,…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy